Development and validation of an enzyme-linked immunosorbent assay for the quantification of gelonin in mouse plasma

References

• Mullard, A. Maturing Antibody-drug Conjugate Pipeline Hits 30. Nat. Rev. Drug Discov. 2013, 12(5), 329–332.
   PubMed Web of Science ®Google Scholar
• Kratz, F.; Senter, P.; Steinhagen, H., Drug Delivery in Oncology: From Basic Research to Cancer Therapy. Wiley-VCH: Weinheim, 2012.
   Google Scholar
• Stirpe, F.; Olsnes, S.; Pihl, A. Gelonin, A New Inhibitor of Protein Synthesis, Nontoxic to intact Cells. Isolation, Characterization, and Preparation of Cytotoxic Complexes with Concanavalin A. J. Biol. Chem. 1980, 255(14), 6947–6953.
   Google Scholar
• Wright, H.T.; Robertus, J.D. The Intersubunit Disulfide Bridge of Ricin is Essential for Cytotoxicity. Arch. Biochem. Biophys. 1987, 256(1), 280–284.
   PubMed Web of Science ®Google Scholar
• Sandvig, K.; van Deurs, B. Endocytosis, Intracellular Transport, and Cytotoxic Action of Shiga Toxin and Ricin. Physiol. Rev. 1996, 76(4), 949–966.
   PubMed Web of Science ®Google Scholar
• Pirie, C.M.; Hackel, B.J.; Rosenblum, M.G.; Wittrup, K.D. Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties. J. Biol. Chem. 2011, 286(6), 4165–4172.
   PubMed Web of Science ®Google Scholar
• Lyu, M.A.; Cao, Y.J.; Mohamedali, K.A.; Rosenblum, M.G. Cell-targeting Fusion Constructs Containing Recombinant Gelonin. Meth. Enzymol. 2012, 502, 167–214.
   PubMed Web of Science ®Google Scholar
• Shin, M.C.; Zhang, J.; Min, K.A.; He, H.; David, A.E.; Huang, Y.; Yang, V.C. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study. Pharm. Res. 2015, 32(8), 2690–2703.
   PubMed Web of Science ®Google Scholar
• Borthakur, G.; Rosenblum, M.G.; Talpaz, M.; Daver, N.; Ravandi, F.; Faderl, S.; Freireich, E.J.; Kadia, T.; Garcia-Manero, G.; Kantarjian, H.; Cortes, J.E. Phase 1 Study of an Anti-CD33 Immunotoxin, Humanized Monoclonal Antibody M195 Conjugated to Recombinant Gelonin (HUM-195/rGEL), in Patients with Advanced Myeloid Malignancies. Haematologica 2013, 98(2), 217–221.
   PubMed Web of Science ®Google Scholar
• Rosenblum, M.G.; Cheung, L.H.; Liu, Y.; Marks, J.W. Design, Expression, Purification, and Characterization, in vitro and in vivo, of an Antimelanoma Single-chain Fv Antibody Fused to the Toxin Gelonin. Cancer Res. 2003, 63(14), 3995–4002.
   PubMed Web of Science ®Google Scholar
• Scott, C.F., Jr.; Lambert, J.M.; Goldmacher, V.S.; Blatter, W.A.; Sobel, R.; Schlossman, S.F.; Benacerraf, B. The Pharmacokinetics and Toxicity of Murine Monoclonal Antibodies and of Gelonin Conjugates of These Antibodies. Int. J. Immunopharmacol. 1987, 9(2), 211–225.
   PubMed Web of Science ®Google Scholar
• Yuan, X.; Lin, X.; Manorek, G.; Howell, S.B. Challenges Associated with the Targeted Delivery of Gelonin to Claudin-expressing Cancer Cells with the Use of Activatable Cell Penetrating Peptides to Enhance Potency. BMC Cancer 2011, 11, 61.
   PubMed Web of Science ®Google Scholar
• Barbieri, L.; Battelli, M.G.; Stirpe, F. Blood Clearance and Organ Distribution and Tissue Concentration of Native, Homopolymerized and IgG-conjugated Ribosome-inactivating Proteins. Xenobiotica 1990, 20(12), 1331–1341.
   PubMed Web of Science ®Google Scholar
• Rosenblum, M.; Zuckerman, J.; Marks, J.; Rotbein, J.; Allen, W.R. A Gelonin-containing Immunotoxin Directed against Human Breast Carcinoma. Molec. Biother. 1992, 4(3), 122–129.
   PubMedGoogle Scholar
• French, R.R.; Penney, C.A.; Browning, A.C.; Stirpe, F.; George, A.J.; Glennie, M.J. Delivery of the Ribosome-inactivating Protein, Gelonin, to Lymphoma Cells via CD22 and CD38 using Bispecific Antibodies. Br. J. Cancer 1995, 71(5), 986–994.
   PubMed Web of Science ®Google Scholar
• Zimmermann, J.; Trommer, W.E. Monoclonal Antibodies to Gelonin: Production and Characterization. Hybridoma 1991, 10(1), 65–76.
   PubMedGoogle Scholar
• Harlow, E.; Lane, D. Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory:Cold Spring Harbor, 1988; p. 726.
   Google Scholar
• Garg, A.; Balthasar, J.P. Physiologically-based Pharmacokinetic (PBPK) Model to Predict IgG Tissue Kinetics in Wild-type and FcRn-knockout Mice. J. Pharmacokinet. Pharmacodyn. 2007, 34(5), 687–709.
   PubMed Web of Science ®Google Scholar
• Abuqayyas, L.; Balthasar, J. P., Pharmacokinetic mAb-mAb interaction: Anti-VEGF mAb Decreases the Distribution of anti-CEA mAb into Colorectal Tumor Xenografts. AAPS J 2012, 14(3), 445–455.
   Google Scholar
• He, X.H.; Shaw, P.C.; Xu, L.H.; Tam, S.C., Site-directed Polyethylene Glycol Modification of Trichosanthin: Effects on its Biological Activities, Pharmacokinetics, and Antigenicity. Life Sci. 1999, 64(14), 1163–1175.
   PubMed Web of Science ®Google Scholar
• Qi, Z.; Whitt, I.; Mehta, A.; Jin, J.; Zhao, M.; Harris, R.C.; Fogo, A.B.; Breyer, M.D., Serial Determination of Glomerular Filtration Rate in Conscious Mice using FITC-inulin Clearance. Am. J. Physiol. Renal. Physiol. 2004, 286(3), F590–F596.
   PubMed Web of Science ®Google Scholar